Overview

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

Status:
Recruiting

Trial end date:
2026-01-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

Novartis

Treatments:

Ipilimumab
Nivolumab
Trametinib